Mar 11, 2020 (Heraldkeepers) — Janus kinase (Jak) is a family of non-tyrosine receptor kinases which play a major role in cytokine signaling. Binding of cytokines (ligand) to receptor results in receptor dimerization and ultimately activates Jak-mediated phosphorylation of the receptor. Jak phosphorylates STAT (Signal Transducer and Activator of Transcription proteins) and STAT dimer carries out the transcription of genes which are critical for signal cascade involved in inflammatory and immune response. Therefore, Janus kinase is used as a target in treatment of autoimmune disorders such as rheumatoid arthritis.
Request for an in-depth table of contents for this report @ https://www.coherentmarketinsights.com/ongoing-insight/toc/2553
Janus Kinase Inhibitor Market Drivers
Jak inhibitors are increasingly preferred for industrial research due to their critical role in immune response signaling. For instance, in June 2018, Eli Lilly and Company announced approval from the U.S. Food and Drug Administration (FDA) for OLUMIANT (baricitinib) — an oral medication for rheumatoid arthritis in adults. Approval was granted for use of baricitinib in combination with methotrexate (MTX) or other disease-modifying antirheumatic drugs (DMARDs) or as monotherapy. The drug inhibits activation of Jak1/2 (Janus kinase 1 and 2) and decreases the production of inflammatory cytokines, thereby inhibiting inflammatory response. Therefore, increasing launch of new drugs is expected to fuel the global janus kinase inhibitor market growth over the forecast period.
Psoriatic arthritis is a form of arthritis which is characterized by red patches of skin with silvery scales. Tofacitinib is a janus kinase inhibitor which modulates cytokines that are required for signaling of inflammatory and immune response. Inclusion of new treatment options is expected to boost the global janus kinase inhibitor market growth over the forecast period. For instance, in December 2017, Pfizer Inc. received approval from the U.S. FDA for XELJANZ (TOFACITINIB) for treatment of adult patients suffering from psoriatic arthritis (PsA).
Get Exclusive Discount on this CMI Report: https://www.coherentmarketinsights.com/insight/request-discount/2553
Furthermore, key manufacturers and research organizations are focused in research and development of new janus kinase inhibitor drugs. For instance, M.D. Anderson Cancer Center, in collaboration with Incyte Corporation, conducted phase -2 clinical trials (study completed in March 2017) to check effect of ruxolitinib in controlling advanced hematological malignancies. Ruxolitinib is an inhibitor of Jak 1 and Jak2 kinases and arrests growth of transformed cells. Therefore, active research and development of new janus kinase inhibitor drugs is expected to fuel the global janus kinase inhibitor market growth over the forecast period.
Janus Kinase Inhibitor Market Regional Analysis
The Janus kinase pathway mediates intracellular signaling of over sixty cytokines. Dysregulation of cytokines causes systemic lupus erythematosus (SLE) — an autoimmune disorder and chronic disease which is characterized by inflammation of connective tissues such as cartilage and blood vessel lining. According to National Center for Biotechnology Information (NCBI), the highest prevalence and incidence of SLE was in recorded in North America (23.2/100 000 person) during the period August 2013- September 2016. Therefore, high prevalence of SLE is expected to boost North America janus kinase inhibitor market growth over the forecast period.
Increasing research and development of launch of new drugs is expected to fuel Asia Pacific janus kinase inhibitor market growth over the forecast period. For instance, Astellas Pharma Inc. — a Japan-based pharmaceutical company — conducted Phase-3 clinical trial (study completed in November 2017) of drug Peficitinib for treatment of Rheumatoid arthritis. The study was conducted to check the superiority of Peficitinib alone and in combination with disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis who did not show sufficient response to DMARDs. Peficitinib is an inhibitor of Jak 1 and Jak that inhibits Interleukin 2 dependent T cell proliferation and STAT5 phosphorylation. These factors are expected to support global janus kinase inhibitor market growth over the forecast period.
Browse Global Strategic Business Report @ https://www.coherentmarketinsights.com/ongoing-insight/janus-kinase-inhibitor-market-2553
Janus Kinase Inhibitor Market Restraints
Regulatory challenges in launch of Janus kinase inhibitors is expected to hinder the market growth. For instance, in April 2017 the U.S. FDA requested Eli Lilly & Company to provide additional clinical data for the dosing of drug Olumiant to characterize safety concerns. Later in April 2018, the FDA denied company the approval for 4mg once daily dose of Olumiant due to safety concerns regarding arterial and venous thrombosis.
Janus Kinase Inhibitor Market Key Players
Some of the key players operating in the global Janus kinase inhibitor market include Eli Lilly and Company, Astellas Pharma Inc., Pfizer Inc., Baxter International Inc., Novartis International AG, Gilead Sciences Inc., Sierra Oncology, Inc., CTI BioPharma Corp., and Incyte Corporation.
Buy This Premium Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/2553
Janus Kinase Inhibitor Market Taxonomy
The global janus kinase inhibitor market is segmented on the basis of drugs, indication, distribution channel and regions.
- Pipeline drugs
- Rheumatoid arthritis
- Psoriatic arthritis
- Systemic lupus erythematosus
By Distribution Channel
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
- North America
- Latin America
- Asia Pacific
- Middle East
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Name: Mr. Shah
Coherent Market Insights 1001 4th Ave,
# 3200 Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
Other Related News:
PARP Inhibitor Market, by Drug Type (Niraparib (Zejula), Olaparib (Lynparza), Rucaparib (Rubraca), and Talazoparib (Talzenna)), by Application (Ovarian Cancer, Breast Cancer, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis 2019 – 2027
Global Hepatitis Drugs Market, By Drug Class (Interferon Alphas, HIV NRTIs, Nucleotide Polymerase/NS5A Inhibitor Combinations, Hepatitis C Protease/NS5A Inhibitor Combinations, NS5A Inhibitors, Nucleotide Polymerase Inhibitors, Nucleoside Analogue Antivirals, and Thrombopoiesis Stimulating Agents), By Disease Type (Hepatitis B, Hepatitis C, and Others), By Route of Administration (Oral and injection), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2019-2027
Peptic Ulcer Drugs Market, By Product Type (Proton Pump Inhibitors, Potassium-Competitive Acid Blocker (P-CAB), Antacids, H2- Antagonists, Antibiotics, Ulcer Protective), By Disease Indication (Gastritis, Gastric Ulcer, Duodenal Ulcer, Gastroesophageal Reflux Disease (GERD)), By Distribution Channel (Hospital Pharmacies, Private Clinics, Drug Stores, Retail Pharmacies, E-Commerce), By Region (North America, Latin America, Europe, Asia Pacific, Middle East and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2019 – 2027
Powered by WPeMatico